An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Preterm Babies With Retinopathy of Prematurity in the United Kingdom (UK)
Launched by BAYER · Mar 11, 2024
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how a medication called aflibercept (Eylea) is used to treat a serious eye condition called retinopathy of prematurity (ROP) in preterm babies in the UK. ROP occurs when the retina, the part of the eye that helps us see, doesn’t develop properly in babies who are born too early. The trial will collect information about babies who are treated with aflibercept using a special dosing device that helps ensure they receive the correct amount of the medication safely. The main goals are to find out how many babies are being treated with this method and to see if there are enough cases to conduct a future study on the long-term safety of aflibercept for these infants.
To be eligible for this study, babies must have been born during the study period and diagnosed with ROP in at least one eye. They also need to have received care in a participating neonatal unit. Importantly, this study only involves collecting information from medical records; there are no additional visits or tests required from the babies or their families. The study will take place from March 2024 to March 2025, but it may continue until April 2027 if more data is needed.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * Eligible infants within the NNRD include those who were:
- • 1. Born during the study period, i.e. from Q4/2023 following market introduction of Eylea PFS+PDD and 31st December 2026, and
- • 2. Received care in a neonatal unit that contributes data to the NNRD and the unit has agreed to participate in the study, and
- • 3. Diagnosed with ROP in any stage in at least one eye.
- Exclusion Criteria:
- • Infants with missing data for gestational age at birth will be excluded.
About Bayer
Bayer is a global healthcare and life sciences company dedicated to advancing health and well-being through innovative research and development. With a strong commitment to improving patient outcomes, Bayer conducts clinical trials across various therapeutic areas, including oncology, cardiology, and women's health. The company leverages cutting-edge science and technology to develop breakthrough therapies, while adhering to the highest standards of ethical practices and regulatory compliance. Through collaboration with healthcare professionals and research institutions, Bayer aims to bring transformative solutions to the market, ultimately enhancing the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Multiple Locations, , United Kingdom
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported